VBI Vaccines Inc (FRA:LO9A)
€ 0.0845 0 (0%) Market Cap: 966,000.00 Enterprise Value: 35.89 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

VBI Vaccines Inc Hepatitis B Portfolio Discussion Transcript

Feb 28, 2023 / 06:00PM GMT
Release Date Price: €0.4231 (+6.90%)
Steven James Seedhouse
Raymond James & Associates, Inc., Research Division - MD & Analyst

Okay. Great. Well, as participants are continuing to join, I just want to welcome, everyone, and thank, everyone, for being with us. I'm Steve Seedhouse, biotech analyst at Raymond James, and really is a pleasure to be hosting this presentation and fireside chat with VBI Vaccines. I'll be joined by Jeff Baxter, President and CEO; and David Anderson, Chief Scientific Officer.

This is potentially a really exciting inflection point for the company. I think they've recently presented some intriguing Phase II data for therapeutic hepatitis B vaccine candidate. And now, of course, are also marketing prophylactic HBV vaccine, PreHevbrio, in the US following approval towards the end of 2021. And VBI is also developing, of course, a pipeline of therapeutic and prophylactic vaccines, including a CMV vaccine for glioblastoma or GBM, a pan-coronavirus vaccine. And so we'll discuss all these programs. And at the outset, I think what I want to do is turn it over to the VBI team, who have prepared some slides,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot